During a live event, Megan Kruse, MD, discussed NCCN guidelines and key therapies for patients with HR-positive metastatic ...

Panelists discuss how treatment selection among Janus kinase (JAK) inhibitors for myelofibrosis involves considering specific ...

Panelists discuss how advancements in understanding myeloproliferative neoplasms are shaping treatment approaches through case studies of intermediate-risk myelofibrosis and advanced polycythemia vera ...

Hany Elmariah, MD, discusses incorporating fedratinib as maintenance therapy in the posttransplant setting to prevent relapse of MPNs and graft-vs-host disease.

The FDA granted regenerative medicine advanced therapy designation to iltamciocel for patients with oropharyngeal dysphagia following head and neck cancer treatment.

Hany Elmariah, MD, discusses dose-limiting toxicities of fedratinib in a phase 1 study exploring the drug in patients with myeloproliferative neoplasms after HCT.

The ACCESS trial is a multicenter, phase 2 trial designed to compare overall survival in patients receiving mismatched unrelated donor peripheral blood stem cells as an allograft source for ...

The precise use of immunotherapy agents in locally advanced head and neck squamous cell carcinoma has not been clearly ...

During a a live event, Virginia Kaklamani, MD, DSc, and participants discussed their experiences using a PI3K/AKT inhibitor ...